호산구성 천식 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 투여 경로별, 환자 속성별, 유통·조달 채널별, 의료 제공 환경별, 지역별 - 업계 예측(2026-2033년)

Global Eosinophilic Asthma Market size was valued at USD 1.15 Billion in 2024 and is poised to grow from USD 1.21 Billion in 2025 to USD 1.81 Billion by 2033, growing at a CAGR of 5.16% during the forecast period (2026-2033).

The global eosinophilic asthma market focuses on therapies for a severe form of asthma characterized by elevated eosinophil levels in the airways. There remains a significant unmet clinical need for patients experiencing recurrent exacerbations despite conventional treatments, prompting pharmaceutical investments in biologics like mepolizumab and benralizumab. Following the introduction of the first anti-IL-5 monoclonal antibody, market growth surged, resulting in enhanced reimbursement frameworks by payers to improve patient access. Increased urban pollution and an aging population are intensifying the burden of severe asthma, leading to a heightened demand for precision medicine. As more patients gain insurance coverage for biologics, drug makers are investing in next-generation therapies targeting interleukin pathways. This evolving landscape offers opportunities for market expansion beyond North America and Europe into regions with improved diagnostics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Eosinophilic Asthma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Eosinophilic Asthma Market Segments Analysis

Global eosinophilic asthma market is segmented by drug product class, route of administration, patient demographics, distribution procurement channel, care setting environment and region. Based on drug product class, the market is segmented into Biologic Therapies, Corticosteroids, Bronchodilators and Leukotriene Modifiers. Based on route of administration, the market is segmented into Subcutaneous Injection, Intravenous Infusion, Oral Ingestion and Inhalation. Based on patient demographics, the market is segmented into Pediatric Patients, Adult Patients and Geriatric Patients. Based on distribution procurement channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on care setting environment, the market is segmented into Hospitals and Specialty Clinics and Home Healthcare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Eosinophilic Asthma Market

The global market for eosinophilic asthma is significantly influenced by the heightened awareness among both the public and healthcare professionals regarding the serious nature of the condition. This awareness has led to earlier diagnoses and more proactive treatment approaches, increasing the patient population eligible for advanced therapies. Educational initiatives and updated medical guidelines highlight the unique characteristics of eosinophilic asthma, prompting healthcare providers to consider targeted interventions. As physicians become more adept at identifying eosinophilic inflammation, there will be a surge in the application of specialized biologics and therapeutic practices within respiratory care. This trend also attracts greater pharmaceutical investment in research, enhancing the pipeline and driving growth in the market.

Restraints in the Global Eosinophilic Asthma Market

The growth of the Global Eosinophilic Asthma market faces significant challenges due to financial barriers associated with the high pricing of biologic treatments. Insurers, providers, and patients encounter strict reimbursement requirements, which often necessitate proof of elevated eosinophil levels and prior treatment failures. These stringent prerequisites can impede timely access to necessary therapies and reduce the overall number of prescriptions written. Consequently, there is a heightened search for more cost-effective alternatives, resulting in slower adoption rates within the market. Even when these treatments demonstrate clinical success, manufacturers may experience constrained revenue growth, fostering a cautious market landscape with limited broader clinical acceptance.

Market Trends of the Global Eosinophilic Asthma Market

The Global Eosinophilic Asthma market is experiencing a significant shift toward personalized biologic therapies, as medical advancements in companion diagnostics and patient stratification gain traction. Physicians are increasingly utilizing biomarker profiles, disease severity, and comorbidity patterns to select targeted treatments, enhancing therapeutic efficacy and minimizing unnecessary side effects. This tailored approach fosters stronger clinician-patient relationships and boosts treatment adherence. Furthermore, it encourages pharmaceutical manufacturers to innovate specialized formulations that align with these individualized regimens, catering to diverse global healthcare environments. As a result, the market is poised for sustainable growth, ultimately leading to improved patient outcomes and enhanced management of eosinophilic asthma.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Eosinophilic Asthma Market Size by Drug Product Class & CAGR (2026-2033)

• Market Overview
• Biologic Therapies
  • Anti-IL-5 Biologics
  • Anti-IL-5R Biologics
  • Anti-IL-4R Biologics
• Corticosteroids
• Bronchodilators
• Leukotriene Modifiers

Global Eosinophilic Asthma Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Subcutaneous Injection
• Intravenous Infusion
• Oral Ingestion
• Inhalation

Global Eosinophilic Asthma Market Size by Patient Demographics & CAGR (2026-2033)

• Market Overview
• Pediatric Patients
• Adult Patients
• Geriatric Patients

Global Eosinophilic Asthma Market Size by Distribution Procurement Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Eosinophilic Asthma Market Size by Care Setting Environment & CAGR (2026-2033)

• Market Overview
• Hospitals and Specialty Clinics
• Home Healthcare Settings

Global Eosinophilic Asthma Market Size & CAGR (2026-2033)

• North America (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • US
  • Canada
• Europe (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiniksa Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pieris Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gossamer Bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Knopp Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synairgen plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 4D Pharma plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations